| 영문 | solid tumor | 한글 | 고형종양 |
|---|---|---|---|
| 설명 | 세포로 꽉 찬 종양을 말함. 백혈병 등의 혈액암과 같이 형태를 취하지 않고 액체인 상태의 암과 대조되는 용어로서 단단한 덩어리로 구성된 악성종양이다. 대부분의 종양이 이에 해당한다. 특히 표피조직에서 기원한 종양을 말한다. |
||
| 영문 | ulcerating tumor | 한글 | 궤양성 종양 |
|---|---|---|---|
| 설명 | 종양의 표면에 궤양이 발생하는 것. 대개, 매우 빨리 자라는 종양에서 혈류 공급이 종양세포의 자라는 속도를 감당하지 못해 종양중심부 조직이 괴사에 빠져 궤양을 형성하는 경우가 많다. 육안으로 보면 빨갛고, 열이나며, 지저분해 보인다. |
||
| 영문 | brain tumor | 한글 | 뇌종양 |
|---|---|---|---|
| 설명 | 뇌종양이란 뇌와 뇌조직에서 생긴 종양을 지칭하는 말이다. 그러나 대개 넓은 의미로 사용할 경우에는 머리뼈속의 공간인 두개강속에 생기는 모든 종양을 이르는 말로 사용된다. 뇌종양은 한정된 공간인 두개강에서 발생하므로 종양이 그다지 크지 않아도 정상적인 조직을 압박하게 되고, 두개강내의 압력을 높인다. 이런 특징에 의해서 뇌종양의 증상은 다른 종양과 달리, 종양 그 자체의 증상보다도 두개내압상승과 정상조직의 압박에 의한 증상이 많다. 두개내압(뇌압)의 상승에 의한 증상으로는 두통, 구토등이 있으며, 지속적인 뇌압상승에 의해서 유두부종(papilledema)이 관찰되기도 한다. 그리고 정상적인 뇌조직의 압박과 종양이 생긴 부위의 기능의 결합에 뇌의 그 부분에 해당하는 기능의 상실을 보게된다. |
||
| 영문 | epithelial tumor | 한글 | 상피성종양 |
|---|---|---|---|
| 설명 | 정상 사람의 조직은 체표면을 덮는 역할을 하는 조직과, 주로 발생기의 중배엽에서 분화한 간엽조직에서 유래하는 결합조직, 뼈, 연골, 지방, 근육, 혈관 등의 조직의 두 계통으로 나눌 수 있다. 전자를 상피성 조직, 후자를 비상피성 조직이라 하며 그 각각을 구성하는 세포를 상피성 세포, 비상피세포라 총칭한다. 상피성 세포에서 기원하는 종양이 상피성 종양이며, 근처의 조직으로 침투나 혈류, 림프의 조직을 타고 원거리의 장기로 이동하지 않는 양성종양에는 선종, 유두종 등이 있고 양성과 반대로 근처의 조직으로 침투, 원격장기로 전이하는 악성종양을 모두 통칭하여 암종(carcinoma)이라고 한다. |
||
| 영문 | medullary tumor | 한글 | 수질성 종양 |
|---|---|---|---|
| 설명 | 암의 병리학적인 분류중 하나. 여러 기관의 암에서 나타나는데 주로 갑상샘암이나 유방암에서 보인다. |
||
| DABP | D site albumin promoter binding protein |
|---|---|
| ESP | early systolic paradox; echo spacing; effective sensory projection; effective systolic pressure; end... |
| GPE | guinea pig embryo; granulocyte colony-stimulating factor promoter element |
| GPEBP | granulocyte colony-stimulating factor promoter element binding protein |
| AFP | Alpha(α) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| AdMLP | Adenovirus major late promoter |
|---|---|
| Ad2MLP | Adenovirus-2 major late promoter |
| COUP-TF | Chicken Ovalbumin Upstream Promoter Transcription Factor |
| COUP-TFII | Chicken ovalbumin upstream promoter transcription factor II |
| IPF-1 | Insulin promoter factor 1 |
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| constituative promoter | An unregulated promoter that allows for continual transcription of itsassociated gene. (09 Oct 1997) |
| promoter | <molecular biology> A region of DNA to which RNA polymerase binds before initiating the transcription of DNA into RNA. The nucleotide at which transcription starts is designated +1 and nucleotides are numbered from this with negative numbers indicating upstream nucleotides and positive downstream nucleotides. most bacterial promoters contain two consensus sequences that seem to be essential for the binding of the polymerase. The first, the Pribnow box, is at about 10 and has the consensus sequence 5' TATAAT 3'. The second, the 35 sequence, is centred about 35 and has the consensus sequence 5' TTGACA 3'. most factors that regulate gene transcription do so by binding at or near the promoter and affecting the initiation of transcription. Much less is known about eukaryote promoters, each of the three RNA polymerases has a different promoter. RNA polymerase I recognises a single promoter for the precursor of rRNA. RNA polymerase II, that transcribes all genes coding for polypeptides, recognises many thousands of promoters. most have the Goldberg Hogness or TATA box that is centred around position 25 and has the consensus sequence 5' TATAAAA 3'. Several promoters have a CAAT box around 90 with the consensus sequence 5' GGCCAATCT 3'. There is increasing evidence that all promoters for housekeeping genes contain multiple copies of a GC rich element that includes the sequence 5' GGGCGG 3'. Transcription by polymerase II is also affected by more distant elements known as enhancers. RNA polymerase III synthesises 5s ribosomal RNA, all tRNAs and a number of small RNAs. The promoter for RNA polymerase III is located within the gene either as a single sequence, as in the 5s RNA gene or as two blocks, as in all tRNA genes. (13 Nov 1997) |
| promoter insertion | <molecular biology> Activation of a gene by the nearby integration of a virus. The long-terminal repeat acts as a promoter for the host gene. A form of insertional mutagenesis. (18 Nov 1997) |
| promoter regions | <genetics> DNA sequences which are recognised (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the pribnow box in bacteria and the tata box in eukaryotes. (12 Dec 1998) |
| down promoter mutation | <molecular biology> A mutation (a change in base pair sequence) in a promoter region, this results in lower gene expression (less transcription of the gene occurs). (09 Oct 1997) |
| tumour promoter | <molecular biology, oncology> Agent that in classical studies of carcinogenesis in rodent skin was able to increase the sensitivity of tumour formation by a previously applied primary carcinogen, but was unable to induce tumours when used alone. Important example was croton oil, active ingredients of which are now believed to be phorbol esters. These are believed to act as analogues of diacylglycerols and may activate protein kinase C. Strictly speaking, not the same as a co carcinogen, which is defined as being active when administered at the same time. Tumour promoters generally are carcinogens when tested more stringently. (18 Nov 1997) |
| up promoter mutation | A mutation that increases the frequency of initiation of transcription. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|